-
公开(公告)号:US11939401B2
公开(公告)日:2024-03-26
申请号:US17698526
申请日:2022-03-18
Applicant: Immatics Biotechnologies GmbH
Inventor: Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
IPC: C07K7/08 , A61K38/17 , A61K39/00 , A61K45/06 , C07K7/06 , C07K14/725 , C12N5/0783 , C12N9/64
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , A61K45/06 , C07K7/06 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12Y304/24065 , A61K2039/5158 , A61K2039/572 , C12N2502/11
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号:US11826410B2
公开(公告)日:2023-11-28
申请号:US17333977
申请日:2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea Mahr , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: A61K39/00 , C07K7/08 , C12N15/115 , C12N5/0783 , C07K14/71 , C07K14/725 , C07K16/28 , C12Q1/6886 , C07K16/18 , G01N33/574 , C07K14/47 , C07K16/30 , C07K7/06 , C07K14/72 , C12N9/12 , C07K16/38 , C07K14/81 , C07K16/40 , C12N9/02 , C07K14/705 , G16B25/00 , G16B25/10 , A61K35/17 , A61K38/00
CPC classification number: A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/705 , C07K14/7051 , C07K14/71 , C07K14/721 , C07K14/8135 , C07K16/18 , C07K16/28 , C07K16/2863 , C07K16/2869 , C07K16/30 , C07K16/38 , C07K16/40 , C12N5/0636 , C12N5/0638 , C12N9/0091 , C12N9/1264 , C12N15/115 , C12Q1/6886 , C12Y116/01 , C12Y207/07031 , G01N33/57484 , G16B25/00 , G16B25/10 , A61K35/17 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2317/34 , C07K2317/76 , C07K2319/40 , C12N2310/16 , C12N2502/11 , C12Q2600/156 , G01N2333/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11629177B2
公开(公告)日:2023-04-18
申请号:US17896923
申请日:2022-08-26
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette Song , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886 , C07K7/04 , A61K38/08 , C07K7/06 , G16B25/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11618774B2
公开(公告)日:2023-04-04
申请号:US17576714
申请日:2022-01-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: A61K39/00 , C07K14/47 , A61P35/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54 , A61K38/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11576955B2
公开(公告)日:2023-02-14
申请号:US17876899
申请日:2022-07-29
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette Song , Linus Backert , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11529400B1
公开(公告)日:2022-12-20
申请号:US17852206
申请日:2022-06-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号:US11214604B2
公开(公告)日:2022-01-04
申请号:US16413439
申请日:2019-05-15
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette Song , Franziska Hoffgaard , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: C07K14/47 , A61P35/02 , A61P35/00 , A61K39/00 , A61K35/17 , A61K45/06 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11208448B2
公开(公告)日:2021-12-28
申请号:US16916443
申请日:2020-06-30
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette Song , Heiko Schuster , Daniel Johannes Kowalewski , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC: A61K35/17 , C07K14/74 , C07K7/04 , C12Q1/6886 , C07K14/47 , A61K39/00 , C07K14/725 , C07K16/18 , C12N5/0783 , G16B25/10 , A61K38/08 , C07K7/06
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20210292365A1
公开(公告)日:2021-09-23
申请号:US17333945
申请日:2021-05-28
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni Weinschenk , Colette Song , Oliver Schoor , Jens Fritsche , Harpreet Singh
IPC: C07K7/08 , G01N33/68 , C07K16/18 , C12N15/115 , A61K39/00 , C07K14/47 , C07K14/725 , C07K7/06 , A61K35/17
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US11071773B2
公开(公告)日:2021-07-27
申请号:US17150617
申请日:2021-01-15
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Claudia Wagner , Julia Leibold , Colette Song
IPC: A61K39/00 , G16B20/20 , A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-